Navigation Links
Molecular imaging detects recurrent prostate cancer
Date:6/6/2010

SALT LAKE CITYFindings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

"Despite definitive treatment, about 30 percent of prostate cancers recur," said David Schuster, M.D., director of the division of nuclear medicine and molecular imaging and assistant professor of radiology at Emory University School of Medicine, Atlanta, Ga. "This troubling statistic led our research team to diligently work on developing new techniques to more effectively detect and diagnose recurrent prostate tumors and associated cancers that have spread to nearby tissues and organs."

According to the authors, a radiotracer known as anti-18F-FACBC could be used to effectively and non-invasively detect and differentiate tumors recurring in the prostate and metastatic cancers that develop, most notably in the surrounding lymph nodes. "This may lead to custom-tailored treatments for prostate cancer patients that cater to their specific tumor type and progression of disease," added Schuster.

The new imaging agent, developed by Dr. Mark Goodman at Emory University, consists of a fluorine-based radioisotope paired with a synthetic amino-acid analog similar to the naturally-occurring amino acid L-leucine. Amino acids are essentially the building blocks of protein, and many cells have a system that controls the transport of amino acids into the cell in order to facilitate the production of new proteins. Upon injection, anti-18F-FACBC is absorbed by various cells by this transport system, but the "uptake," or admission of the agent, is much higher in aggressively multiplying cancer cells, which need more of these proteins in order to proliferate.

Researchers scanned 83 patients suspected of having recurrent prostate cancer using a hybrid positron emission tomography and computed tomography (PET/CT) system, a molecular imaging technique that displays both anatomical information and physiological processes in the body. Resulting scans were evaluated to determine the presence of recurrent prostate tumors and outlying tumors that had metastasized, or spread, to other tissues, including those of nearby bones and lymph nodes that tend be to a target for cancer metastases. The agent was able to positively identify recurrent carcinomas in the prostate region with 74-percent accuracy, and metastatic cancers with 96-percent accuracy, catching even small tumors within lymph nodes that other imaging agents could not detect. The ability to differentiate tumors recurring in the prostate from metastatic cancers with high accuracy is the most promising aspect of this PET radiotracer.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Molecular Signatures in Post-Mortem Brain Tissue of Younger Individuals at High Risk for Alzheimer's Disease
2. Molecular imaging and CT colonography team up to bring comfort to patients
3. Acupunctures molecular effects pinned down
4. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
5. Scientists discover the molecular heart of collective behavior
6. News from Molecular Medicine
7. Molecular marker could help spot pancreatic cancer early
8. Molecular discovery points to new therapies for brain tumors
9. USC researchers discover new molecular subtype of brain cancer
10. The Association for Molecular Pathology celebrates ruling in DNA patent case
11. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Qualitative research, which is primarily based on ... of the program, policy or intervention being studied. Both quantitative and qualitative research ... In a new brief released today, Reading Qualitative Educational Policy Research, William Mathis ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provide the playing surface for the 2016 NCAA Men’s National Collegiate ... for the men’s volleyball championship to be held May 5-7 at Pennsylvania State ...
(Date:5/4/2016)... ... May 04, 2016 , ... Level 10 Head Over Heels Athletic ... to the University of Arizona for the fall of 2019. , After a ... Brovedani’s commitment to the GymCats came from her connection with the coaching staff and ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... ... 04, 2016 , ... A new collaboration will give more researchers access to ... (DCRI) and analytics leader SAS will provide researchers worldwide with data management and analytics ... Health System. , The DCRI and SAS share the goal of greater transparency ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... ACME Markets, Delaware ... Delaware County Councilman Dave White announced ... ACME pharmacies across Delaware County ... Prevention (CDC), naloxone has saved 26,463 lives nationwide over the past ... Delaware County were authorized to administer naloxone to overdose ...
(Date:5/3/2016)... FLINT, Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... The company released a video of two patients who tell their personal story and encourage ... hepatitis.   Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: